TailorMed

TailorMedTailorMed
TailorMed

TailorMed

Connects patients, providers, pharmacies, and life science companies to improve treatment affordability.

DR 25Speed 622016Active192New York, United States
Rate

About

TailorMed provides an end-to-end medication success platform that removes access, affordability, and adherence barriers for patients. Their solutions, including TailorMed Core, Connect, and Complete, manage the full patient medication journey from prescription to therapy. TailorMed serves patients, providers, hospitals, clinics, pharmacies, and life science partners through its extensive network.
Frequently asked

What does TailorMed do?

TailorMed provides an end-to-end medication success platform that removes access, affordability, and adherence barriers for patients. Their solutions, including TailorMed Core, Connect, and Complete, manage the full patient medication journey from prescription to therapy. TailorMed serves patients, providers, hospitals, clinics, pharmacies, and life science partners through its extensive network.

What is TailorMed's revenue?

StartupHub estimates TailorMed's annual revenue at $39.6M (range $29.1M to $90.8M, 67% confidence), based on comparable companies in the sector.

What is TailorMed's valuation?

StartupHub estimates TailorMed's effective valuation at $295.0M (range $177.5M to $426.0M, 17% confidence), based on comparable companies in the sector.

How much funding has TailorMed raised?

TailorMed has raised a total of $71M in funding. The most recent round on record is Series C.

Where is TailorMed headquartered?

TailorMed is headquartered in New York, United States.

When was TailorMed founded?

TailorMed was founded in 2016.

What industry does TailorMed operate in?

TailorMed operates in Healthcare, Patient, Insurance, HealthTech, Patient Assistance Programs, Pharmaceuticals.

How many employees does TailorMed have?

TailorMed has approximately 192 people on record.

HEADCOUNT
192
DOMAIN RATING
25
Comments

No comments yet. Be the first to share your take.